Muted end to Bourla's first year atop Pfizer

Ahead of the opening bell, shares in New York-based drug giant Pfizer (NYSE: PFE) were off a hefty 1.5% on Tuesday, as the firm announced a disappointing quarterly profit result, below analysts’ expectations.

A relatively weak performance from breast cancer option Ibrance (palbociclib) was one of the reasons for the slow finish to 2019. Fourth-quarter revenues were $12.7 billion, while full-year revenues came in at $51.8 billion, hitting the FT’s consensus forecast.

Following Generally Accepted Accounting Principles (GAAP), the earnings per share figure was $2.95 for the year and $0.55 for the final quarter.